Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Vomiting × netupitant × Clear all

Phase

Phase 2 2 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 1 Neoplasms 1 Nausea 1

Interventions

Olanzapine 2 netupitant, palosentron drug combination 1 netupitant 1 ginger extract 1 Therapeutics 1 Palonosetron 1 Dexamethasone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03040726 2023-10-17

Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

M.D. Anderson Cancer Center

Phase 2/3 Completed

53 enrolled 15 charts

Nausea, Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon ⚡